Patient characteristics before transplantation (n= 34)
| Clinical parameter . | Value . | Frequency, no.* . |
|---|---|---|
| Median age, y (range) | 41 (23-61) | 34 |
| Sex: M/F | 8/26 | 34 |
| Median skin score: mRSS (range) | 30 (3-48) | 34 |
| Median DLCOadj,† % (range) | 61 (40-83) | 33 |
| Median FVC, % (range) | 71 (27-103) | 34 |
| HRCT of chest | ||
| Abnormal | 27 | 34 |
| Ground-glass | 12 | 34 |
| Interstitial fibrosis | 25 | 34 |
| Normal | 7 | 34 |
| Alveolitis by BAL | 16 | 25 |
| Median ejection fraction, % (range) | 65 (47-80) | 32 |
| Median serum creatinine level, mg/dL (range) | 0.7 (0.4-1.7) | 34 |
| Median mHAQ score (range) | 1.88 (0.25-2.88) | 30 |
| Hypothyroidism | 9 | 34 |
| Organ dysfunction | ||
| Lung‡ | 34 | 34 |
| Kidney§ | 2 | 34 |
| Heart‖ | 9 | 34 |
| Gastrointestinal tract¶ | 23 | 34 |
| Autoantibodies | ||
| Antinuclear antibodies | 25 | 33 |
| Scl-70 | 11 | 34 |
| Anticentromere | 0 | 27 |
| Disease duration, mo (range)# | 21 (4-51) | 34 |
| Immune-based therapy before HDIT | ||
| Corticosteroids | 22 | 34 |
| Cyclophosphamide | 15 | 34 |
| Methotrexate | 13 | 34 |
| D-penicillamine | 10 | 34 |
| Hydroxychloroquine | 6 | 34 |
| Etanercept | 5 | 34 |
| Cyclosporine | 3 | 34 |
| Relaxin | 2 | 34 |
| Imuran | 1 | 34 |
| Other | 4 | 34 |
| Clinical parameter . | Value . | Frequency, no.* . |
|---|---|---|
| Median age, y (range) | 41 (23-61) | 34 |
| Sex: M/F | 8/26 | 34 |
| Median skin score: mRSS (range) | 30 (3-48) | 34 |
| Median DLCOadj,† % (range) | 61 (40-83) | 33 |
| Median FVC, % (range) | 71 (27-103) | 34 |
| HRCT of chest | ||
| Abnormal | 27 | 34 |
| Ground-glass | 12 | 34 |
| Interstitial fibrosis | 25 | 34 |
| Normal | 7 | 34 |
| Alveolitis by BAL | 16 | 25 |
| Median ejection fraction, % (range) | 65 (47-80) | 32 |
| Median serum creatinine level, mg/dL (range) | 0.7 (0.4-1.7) | 34 |
| Median mHAQ score (range) | 1.88 (0.25-2.88) | 30 |
| Hypothyroidism | 9 | 34 |
| Organ dysfunction | ||
| Lung‡ | 34 | 34 |
| Kidney§ | 2 | 34 |
| Heart‖ | 9 | 34 |
| Gastrointestinal tract¶ | 23 | 34 |
| Autoantibodies | ||
| Antinuclear antibodies | 25 | 33 |
| Scl-70 | 11 | 34 |
| Anticentromere | 0 | 27 |
| Disease duration, mo (range)# | 21 (4-51) | 34 |
| Immune-based therapy before HDIT | ||
| Corticosteroids | 22 | 34 |
| Cyclophosphamide | 15 | 34 |
| Methotrexate | 13 | 34 |
| D-penicillamine | 10 | 34 |
| Hydroxychloroquine | 6 | 34 |
| Etanercept | 5 | 34 |
| Cyclosporine | 3 | 34 |
| Relaxin | 2 | 34 |
| Imuran | 1 | 34 |
| Other | 4 | 34 |
BAL indicates bronchoalveolar lavage.
Number of patients with available results for the given parameter.
Adjusted for hemoglobin concentration.
Lung dysfunction was defined as diffusion capacity of the lung for carbon monoxide adjusted for hemoglobin levels below 70% and/or forced vital capacity below 70%.
Renal dysfunction was defined as prior history of renal crisis.
Cardiac dysfunction was defined as ejection fraction below 50%, electrical conduction abnormalities, pulmonary hypertension, or pericardial effusion.
Gastrointestinal dysfunction was defined as esophageal or bowel dysfunction including a history of parenteral nutrition.
Time from onset of first non-Raynaud symptoms.